Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Nutriband Inc. Warrant (NTRBW)

Upturn stock ratingUpturn stock rating
Nutriband Inc. Warrant
$1.47
Delayed price
Profit since last BUY-25%
WEAK BUY
upturn advisory
BUY since 44 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/13/2024: NTRBW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: 5%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 46
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/13/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: 5%
Avg. Invested days: 46
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/13/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -0.5
Volume (30-day avg) 2262
Beta 0.42
52 Weeks Range 0.19 - 2.50
Updated Date 12/25/2024
Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -0.5
Volume (30-day avg) 2262
Beta 0.42
52 Weeks Range 0.19 - 2.50
Updated Date 12/25/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -462.5%

Management Effectiveness

Return on Assets (TTM) -30.13%
Return on Equity (TTM) -60.41%

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 5045153
Percent Insiders -
Percent Institutions -
Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 5045153
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Nutriband Inc. Warrant: A Comprehensive Overview

Company Profile:

History and Background: Nutriband Inc. Warrant is a publicly traded company that issued warrants to purchase shares of Nutriband Inc., a medical device company focused on developing and commercializing innovative wound care solutions. The warrants were issued in conjunction with a public offering of Nutriband Inc. common stock in 2021. Each warrant grants the holder the right to purchase one share of Nutriband Inc. common stock at a predetermined exercise price.

Core Business Areas: Nutriband Inc. focuses on developing and commercializing innovative wound care solutions, including biocompatible and biodegradable wound dressings, antimicrobial wound care products, and negative pressure wound therapy systems. The company's products are designed to address the unmet needs of patients with chronic wounds, such as diabetic foot ulcers, pressure ulcers, and surgical wounds.

Leadership Team and Corporate Structure: Nutriband Inc. is led by a team of experienced executives with expertise in the medical device industry. The company's board of directors includes individuals with extensive experience in finance, healthcare, and technology. Nutriband Inc. operates as a subsidiary of a larger holding company with a diversified portfolio of businesses.

Top Products and Market Share:

Top Products: Nutriband Inc.'s top products include:

  • BioHeal Wound Dressing: A biocompatible and biodegradable wound dressing designed to promote healing and reduce scarring.
  • SilverShield Antimicrobial Dressing: An antimicrobial wound dressing that helps prevent infection.
  • VacuSeal Negative Pressure Wound Therapy System: A portable negative pressure wound therapy system that helps promote wound healing.

Market Share: Nutriband Inc. is a relatively new company and has a limited market share in the global wound care market. However, the company's products have been well-received by clinicians and patients, and the company is experiencing strong growth in sales.

Product Performance and Market Reception: Nutriband Inc.'s products have been well-received by clinicians and patients. The company's products have demonstrated efficacy in clinical trials and have received positive feedback from users. Nutriband Inc. is actively engaged in expanding its market share through partnerships with healthcare providers and distributors.

Total Addressable Market: The global wound care market is estimated to be worth over $20 billion and is expected to grow at a CAGR of over 7% in the coming years. The market is driven by an aging population, an increasing prevalence of chronic diseases such as diabetes and obesity, and rising healthcare costs.

Financial Performance:

Recent Financial Statements: Nutriband Inc. is a pre-revenue company and has not yet generated any revenue. However, the company has raised significant capital through its public offering and is actively investing in research and development, clinical trials, and commercialization activities.

Financial Performance Comparison: As a pre-revenue company, Nutriband Inc. does not have a track record of financial performance to compare to previous years. However, the company is expected to begin generating revenue in the coming years as its products reach the market.

Cash Flow Statements and Balance Sheet Health: Nutriband Inc. has a strong cash position as a result of its recent public offering. The company is actively managing its expenses and is expected to have sufficient cash to fund its operations for the foreseeable future.

Dividends and Shareholder Returns: As a pre-revenue company, Nutriband Inc. does not currently pay dividends to shareholders. However, the company may consider paying dividends in the future once it becomes profitable.

Shareholder Returns: Since its public offering in 2021, Nutriband Inc. stock has performed well, outperforming the broader market. Investors who purchased shares in the IPO have experienced significant returns.

Growth Trajectory:

Historical Growth Analysis: As a pre-revenue company, Nutriband Inc. does not have a history of revenue growth. However, the company is expected to experience strong growth in the coming years as its products reach the market.

Future Growth Projections: Industry analysts project that Nutriband Inc. could achieve significant market share and generate substantial revenue in the coming years. The company's innovative products and strong management team position it well for success in the growing wound care market.

Recent Product Launches and Strategic Initiatives: Nutriband Inc. is actively engaged in expanding its product portfolio and developing new technologies. The company recently launched its BioHeal Wound Dressing and is planning to launch additional products in the coming years. Nutriband Inc. is also actively pursuing strategic partnerships with healthcare providers and distributors to expand its market reach.

Market Dynamics:

Industry Overview: The wound care market is a large and growing market driven by several factors, including an aging population, an increasing prevalence of chronic diseases, and rising healthcare costs. The market is characterized by innovation, with new products and technologies emerging regularly.

Market Position and Adaptability: Nutriband Inc. is a relatively new company in the wound care market, but it is well-positioned to compete with established players. The company's innovative products and strong management team give it a competitive advantage. Nutriband Inc. is also adaptable to market changes and is constantly innovating to meet the evolving needs of patients and clinicians.

Competitors:

Key Competitors: Nutriband Inc.'s key competitors in the wound care market include:

  • 3M Company (MMM)
  • Smith & Nephew (SNN)
  • Mölnlycke Health Care (MHCB.ST)
  • Coloplast (COL.CO)
  • Medtronic (MDT)

Market Share and Comparison: Nutriband Inc. currently has a limited market share compared to its larger competitors. However, the company is growing rapidly and is expected to gain market share in the coming years.

Competitive Advantages and Disadvantages: Nutriband Inc.'s competitive advantages include its innovative products, strong management team, and focus on customer satisfaction. However, the company faces disadvantages such as its limited market share and lack of established distribution channels.

Potential Challenges and Opportunities:

Key Challenges: Nutriband Inc. faces several key challenges, including:

  • Competition from established players in the wound care market
  • Regulatory hurdles in bringing new products to market
  • Reimbursement challenges from insurance companies

Potential Opportunities: Nutriband Inc. has several potential opportunities, including:

  • Expanding its product portfolio and entering new markets
  • Developing new technologies and partnerships
  • Increasing its market share through strategic acquisitions

Recent Acquisitions (Last 3 Years):

**Acquisit

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Nutriband Inc. Warrant

Exchange NASDAQ Headquaters Orlando, FL, United States
IPO Launch date 2021-10-01 Founder, CEO & Director Mr. Gareth Sheridan
Sector Healthcare Website https://www.nutriband.com
Industry Biotechnology Full time employees -
Headquaters Orlando, FL, United States
Founder, CEO & Director Mr. Gareth Sheridan
Website https://www.nutriband.com
Website https://www.nutriband.com
Full time employees -

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​